Buysmann S - Search Results

1

CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes.

Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJ, Hack CE. Wolbink GJ, et al. Among authors: buysmann s. J Immunol. 1996 Jul 1;157(1):473-9. J Immunol. 1996. PMID: 8683153

2

Pretreatment with divided doses of steroids strongly decreases side effects of OKT3.

Bemelman FJ, Buysmann S, Surachno J, Wilmink JM, Schellekens PT, ten Berge IJ. Bemelman FJ, et al. Among authors: buysmann s. Kidney Int. 1994 Dec;46(6):1674-9. doi: 10.1038/ki.1994.467. Kidney Int. 1994. PMID: 7700026 Free article.

3

Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3.

Buysmann S, Bemelman FJ, Schellekens PT, van Kooyk Y, Figdor CG, ten Berge IJ. Buysmann S, et al. Blood. 1996 Jan 1;87(1):404-11. Blood. 1996. PMID: 8547669 Free article.

4

Different CD3/T cell receptor monoclonal antibodies have distinct capacities to induce adhesion of T lymphocytes to endothelium.

Buysmann S, Schellekens PT, Tax WJ, ten Berge IJ. Buysmann S, et al. J Lab Clin Med. 1997 Jul;130(1):91-101. doi: 10.1016/s0022-2143(97)90063-9. J Lab Clin Med. 1997. PMID: 9242371

5

Administration of OKT3 as a two-hour infusion attenuates first-dose side effects.

Buysmann S, Hack CE, van Diepen FN, Surachno J, ten Berge IJ. Buysmann S, et al. Transplantation. 1997 Dec 15;64(11):1620-3. doi: 10.1097/00007890-199712150-00024. Transplantation. 1997. PMID: 9415571

6

Effects of divided doses of steroids on side effects, cytokines, and activation of complement and granulocytes, coagulation and fibrinolysis after OKT3.

Bemelman FJ, Buysmann S, Wilmink JM, Surachno S, Hack CE, Schellekens PT, ten Berge RJ. Bemelman FJ, et al. Among authors: buysmann s. Transplant Proc. 1994 Dec;26(6):3096-7. Transplant Proc. 1994. PMID: 7527944 Clinical Trial. No abstract available.

7

Consequences of OKT3 administration via continuous infusion as compared to bolus infusion.

ten Berge RJ, Buysmann S, van Diepen FN, Surachno S, Hack CE. ten Berge RJ, et al. Among authors: buysmann s. Transplant Proc. 1996 Dec;28(6):3217-20. Transplant Proc. 1996. PMID: 8962246 Clinical Trial. No abstract available.

8

Guidelines for the optimal use of muromonab CD3 in transplantation.

ten Berge IJ, Parlevliet KJ, Raasveld MH, Buysmann S, Bemelman FJ, Schellekens PT. ten Berge IJ, et al. Among authors: buysmann s. BioDrugs. 1999 Apr;11(4):277-84. doi: 10.2165/00063030-199911040-00006. BioDrugs. 1999. PMID: 18031137

9

Increased dermal expression of ICAM-1 and VCAM-1 after administration of OKT3 in man.

Buysmann S, van Diepen FN, Surachno S, Pals ST, ten Berge RJ. Buysmann S, et al. Clin Nephrol. 1996 Aug;46(2):84-91. Clin Nephrol. 1996. PMID: 8869784

10

Biphasic granulocytopenia after administration of the first dose of OKT3.

Bemelman FJ, Buysmann S, Yong SL, van Diepen FN, Schellekens PT, ten Berge RJ. Bemelman FJ, et al. Among authors: buysmann s. J Lab Clin Med. 1995 Dec;126(6):571-9. J Lab Clin Med. 1995. PMID: 7490516

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters